PMID- 36190006
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221206
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 10
DP  - 2022 Oct
TI  - Assessment of intralesional injection of botulinum toxin type A in hypertrophic 
      scars and keloids: Clinical and pathological study.
PG  - e15748
LID - 10.1111/dth.15748 [doi]
AB  - Keloids and hypertrophic scars are cosmetic problems with significant morbidity. 
      Many clinical modalities were tried in order to modulate the disfigurement 
      related to these pathologic scars. To evaluate the clinical and histopathological 
      effects of Botulinum toxin type A (BTX-A) injection on keloids and hypertrophic 
      scars. Twelve patients with keloids and 8 with hypertrophic scars were enrolled 
      in this study. Botulinum toxin type A was injected intralesional (1 
      session/month) for three sessions. Clinical outcome was assessed via Vancouver 
      Scar Scale (VSS), Observer Scar Assessment Scale (OSAS), and the Patient Scar 
      Assessment Scale (PSAS). Histologic grading scores were used to assess the 
      changes in the quality of collagen and elastic tissues and image analysis was 
      used to detect their quantitative morphometric changes. This study showed a high 
      statistically significant difference between baseline and the result after each 
      of the three sessions of injection and 3, 6 months after the last session 
      regarding VSS, OSAS, and PSAS with p value </=0.001 for each. The study also showed 
      that there was a statistically significant difference between the histopathologic 
      findings before injection of BTX and 1 month after the third session regarding 
      all parameters used. Botulinum toxin type A can be a good therapeutic maneuver 
      for management of keloid and hypertrophic scars with significant clinical and 
      histologic improvement.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Khatery, Basma H M
AU  - Khatery BHM
AD  - Department of Dermatology, STDs and Andrology, Faculty of Medicine, Fayoum 
      University, Fayoum, Egypt.
FAU - Hussein, Heba A
AU  - Hussein HA
AD  - Department of Dermatology, STDs and Andrology, Faculty of Medicine, Fayoum 
      University, Fayoum, Egypt.
FAU - Abd-El-Raheem, Talal A
AU  - Abd-El-Raheem TA
AD  - Department of Dermatology, STDs and Andrology, Faculty of Medicine, Fayoum 
      University, Fayoum, Egypt.
FAU - El Hanbuli, Hala M
AU  - El Hanbuli HM
AUID- ORCID: 0000-0003-4147-1397
AD  - Pathology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
FAU - Yassen, Noha N
AU  - Yassen NN
AD  - Pathology Department, Medical Research and Clinical Studies Institute, National 
      Research Centre, Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220815
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 9007-34-5 (Collagen)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - *Botulinum Toxins, Type A/therapeutic use
MH  - *Cicatrix, Hypertrophic/diagnosis/drug therapy/pathology
MH  - Collagen/therapeutic use
MH  - Humans
MH  - Injections, Intralesional
MH  - *Keloid/diagnosis/drug therapy/pathology
MH  - *Sleep Apnea, Obstructive/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - botulinum toxin-A
OT  - hypertrophic scar
OT  - keloid
EDAT- 2022/10/04 06:00
MHDA- 2022/10/05 06:00
CRDT- 2022/10/03 07:33
PHST- 2022/07/07 00:00 [revised]
PHST- 2022/06/16 00:00 [received]
PHST- 2022/07/28 00:00 [accepted]
PHST- 2022/10/03 07:33 [entrez]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
AID - 10.1111/dth.15748 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Oct;35(10):e15748. doi: 10.1111/dth.15748. Epub 2022 Aug 15.